🚀 VC round data is live in beta, check it out!
Inogen Valuation Multiples
Discover revenue and EBITDA valuation multiples for Inogen and similar public comparables like Deltex Medical Group, Zepp Health, Sight Sciences, JETEMA Co. and more.
Inogen Overview
About Inogen
Inogen Inc is a medical technology company that develops and manufactures portable oxygen concentrators used to deliver oxygen therapy to patients with chronic respiratory conditions. Its key product, the Inogen One system, is a lightweight alternative to traditional, stationary oxygen concentrator systems and oxygen tanks. The firm sells its products to home medical equipment providers and also rents products directly to patients. Internationally, It sells its products through distributors large gas companies, and home oxygen providers. It generates the majority of its revenue in the United States.
Founded
2001
HQ
Employees
766
Website
Financials (LTM)
EV
$79M
Inogen Financials
Inogen reported last 12-month revenue of $354M and EBITDA of $3M.
In the same LTM period, Inogen generated $157M in gross profit, $3M in EBITDA, and had net loss of ($22M).
Revenue (LTM)
Inogen P&L
In the most recent fiscal year, Inogen reported revenue of $349M and EBITDA of $3M.
Inogen expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $354M | XXX | $349M | XXX | XXX | XXX |
| Gross Profit | $157M | XXX | $154M | XXX | XXX | XXX |
| Gross Margin | 44% | XXX | 44% | XXX | XXX | XXX |
| EBITDA | $3M | XXX | $3M | XXX | XXX | XXX |
| EBITDA Margin | 1% | XXX | 1% | XXX | XXX | XXX |
| EBIT Margin | (8%) | XXX | (9%) | XXX | XXX | XXX |
| Net Profit | ($22M) | XXX | ($23M) | XXX | XXX | XXX |
| Net Margin | (6%) | XXX | (7%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Inogen Stock Performance
Inogen has current market cap of $182M, and enterprise value of $79M.
Market Cap Evolution
Inogen's stock price is $6.67.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $79M | $182M | -0.1% | XXX | XXX | XXX | $-0.84 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialInogen Valuation Multiples
Inogen trades at 0.2x EV/Revenue multiple, and 28.9x EV/EBITDA.
EV / Revenue (LTM)
Inogen Financial Valuation Multiples
As of April 11, 2026, Inogen has market cap of $182M and EV of $79M.
Equity research analysts estimate Inogen's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Inogen has a P/E ratio of (8.1x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $182M | XXX | $182M | XXX | XXX | XXX |
| EV (current) | $79M | XXX | $79M | XXX | XXX | XXX |
| EV/Revenue | 0.2x | XXX | 0.2x | XXX | XXX | XXX |
| EV/EBITDA | 28.9x | XXX | 29.5x | XXX | XXX | XXX |
| EV/EBIT | (2.7x) | XXX | (2.6x) | XXX | XXX | XXX |
| EV/Gross Profit | 0.5x | XXX | 0.5x | XXX | XXX | XXX |
| P/E | (8.1x) | XXX | (8.0x) | XXX | XXX | XXX |
| EV/FCF | (3.0x) | XXX | (3.7x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Inogen Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Inogen Margins & Growth Rates
Inogen's revenue in the last 12 month grew by 6%.
Inogen's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.2M for the same period.
Inogen's rule of 40 is 7% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Inogen's rule of X is 16% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Inogen Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 6% | XXX | 6% | XXX | XXX | XXX |
| EBITDA Margin | 1% | XXX | 1% | XXX | XXX | XXX |
| EBITDA Growth | 82% | XXX | 8% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 7% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 16% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 28% | XXX | 28% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 19% | XXX | 19% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 6% | XXX | 6% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 53% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Inogen Public Comps
See public comps and valuation multiples for other Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Deltex Medical Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Zepp Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Sight Sciences | XXX | XXX | XXX | XXX | XXX | XXX |
| JETEMA Co. | XXX | XXX | XXX | XXX | XXX | XXX |
| Surgical Science | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Inogen M&A Activity
Inogen acquired XXX companies to date.
Last acquisition by Inogen was on XXXXXXXX, XXXXX. Inogen acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Inogen
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialInogen Investment Activity
Inogen invested in XXX companies to date.
Inogen made its latest investment on XXXXXXXX, XXXXX. Inogen invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Inogen
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Inogen
| When was Inogen founded? | Inogen was founded in 2001. |
| Where is Inogen headquartered? | Inogen is headquartered in United States. |
| How many employees does Inogen have? | As of today, Inogen has over 766 employees. |
| Who is the CEO of Inogen? | Inogen's CEO is Kevin R. M. Smith. |
| Is Inogen publicly listed? | Yes, Inogen is a public company listed on Nasdaq. |
| What is the stock symbol of Inogen? | Inogen trades under INGN ticker. |
| When did Inogen go public? | Inogen went public in 2014. |
| Who are competitors of Inogen? | Inogen main competitors are Deltex Medical Group, Zepp Health, Sight Sciences, JETEMA Co.. |
| What is the current market cap of Inogen? | Inogen's current market cap is $182M. |
| What is the current revenue of Inogen? | Inogen's last 12 months revenue is $354M. |
| What is the current revenue growth of Inogen? | Inogen revenue growth (NTM/LTM) is 6%. |
| What is the current EV/Revenue multiple of Inogen? | Current revenue multiple of Inogen is 0.2x. |
| Is Inogen profitable? | Yes, Inogen is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Inogen? | Inogen's last 12 months EBITDA is $3M. |
| What is Inogen's EBITDA margin? | Inogen's last 12 months EBITDA margin is 1%. |
| What is the current EV/EBITDA multiple of Inogen? | Current EBITDA multiple of Inogen is 28.9x. |
| What is the current FCF of Inogen? | Inogen's last 12 months FCF is ($26M). |
| What is Inogen's FCF margin? | Inogen's last 12 months FCF margin is (7%). |
| What is the current EV/FCF multiple of Inogen? | Current FCF multiple of Inogen is (3.0x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.